Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome

Heart

Volumn 86, Issue 5, 2001, Pages 553-558

  Budts, W ^a   Van Pelt, N ^c   Gillyns, H ^c   Gewillig, M ^b   Van de Weft, F ^a   Janssens, S ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b University Hospital   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Eisenmenger syndrome; Nitric oxide; Pulmonary hypertension

Indexed keywords

CYCLIC GMP; NITRIC OXIDE; VASODILATOR AGENT;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; COMORBIDITY; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EISENMENGER COMPLEX; FEMALE; HEART RIGHT LEFT SHUNT; HUMAN; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REBOUND; TREATMENT OUTCOME;

EID: 0034778877     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.86.5.553     Document Type: Article

References (41)

1. Cardiac output and related measurements and pressure values in the right heart and associated vessels, together with an analysis of the hemodynamic response to the inhalation of high oxygen mixtures in healthy subjects
2. High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium
3. Eisenmenger's syndrome
4. Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats
5. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide
6. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
7. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics
8. Inhaled nitric oxide: Its effects on pulmonary circulation and airway smooth muscle cells
9. Inhaled nitric oxide for right ventricular dysfunction following cardiac transplantation
10. The influence of preoperative patient characteristics on early and late survival following cardiac transplantation
11. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
12. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: Predictive ability and consequences on haemodynamics and gas exchange
13. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn
14. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients
15. Evaluation of a continuous thermodilution cardiac output catheter
16. A continuous cardiac output computer based on thermodilution principles
17. An evaluation of thermodilution cardiac output measurement using the Swan-Ganz catheter
18. The effect of an intracardiac left-right shunt on thermodilution measurements of cardiac output. An extracorporeal circulation model
19. Role of pharmacologic tests in the treatment of primary pulmonary hypertension
20. Pulmonary hypertension in pediatric patients
21. Pulmonary vascular obstructive disease
22. Severe pulmonary hypertension in congenital heart disease: A review of Eisenmenger syndrome
23. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome
24. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy
25. Calcium channel blockers in primary pulmonary hypertension
26. Therapeutic application of calcium-channel antagonists for pulmonary hypertension
27. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)
28. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension
29. Comparative studies of hemodynamics under prostacyclin and nifedipine in patients with Eisenmenger syndrome
30. Eisenmenger syndrome in adults
31. Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger's mechanism in children
32. Inhaled nitric oxide reduces the utilization of extracorporeal membrane oxygenation in persistent pulmonary hypertension of the newborn
33. Management of labor in Eisenmenger syndrome with inhaled nitric oxide
34. Favorable response of Eisenmenger syndrome to inhaled nitric oxide during pregnancy
35. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin
36. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension
37. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
38. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
39. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
40. Kinetics of methaemoglobin and serum nitrogen oxide production during inhalation of nitric oxide in volunteers
41. Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats